117 related articles for article (PubMed ID: 36029371)
1. Factors affecting prognosis in hepatocellular carcinoma patients post-transarterial chemoembolization.
Prateepchaiboon T; Chang A; Pungpipattrakul N; Akarapatima K; Rattanasupar A; Songjamrat A; Pakdeejit S; Piratvisuth T
Indian J Gastroenterol; 2022 Aug; 41(4):352-361. PubMed ID: 36029371
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
3. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma.
Jeong SO; Kim EB; Jeong SW; Jang JY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ; Goo DE; Park SY
Gut Liver; 2017 May; 11(3):409-416. PubMed ID: 28208001
[TBL] [Abstract][Full Text] [Related]
4. Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Grasu M; Pâslaru L; Dumitru R; Lupescu I; Constantin G; Croitoru A; Gheorghe L
J Gastrointestin Liver Dis; 2018 Dec; 27(4):409-417. PubMed ID: 30574623
[TBL] [Abstract][Full Text] [Related]
5. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
Kim NH; Lee T; Cho YK; Kim BI; Kim HJ
J Gastroenterol Hepatol; 2018 Jul; 33(7):1397-1406. PubMed ID: 29314222
[TBL] [Abstract][Full Text] [Related]
6. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
7. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
10. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors.
Sohn W; Choi MS; Cho JY; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Yoo BC
Gut Liver; 2014 Sep; 8(5):543-51. PubMed ID: 25071073
[TBL] [Abstract][Full Text] [Related]
11. Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma.
Bannangkoon K; Hongsakul K; Tubtawee T; McNeil E; Sriplung H; Chongsuvivatwong V
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3545-3550. PubMed ID: 30583681
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Müller L; Hahn F; Mähringer-Kunz A; Stoehr F; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Pitton MB; Düber C; Fehrenbach U; Auer TA; Gebauer B; Kloeckner R
United European Gastroenterol J; 2022 Feb; 10(1):41-53. PubMed ID: 34918471
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study.
Zeng G; Zou B; Li Y; Lin E; Liu X; Li P; Chen J; Zhang B; Jia Y; Cai C; Li J
J Invest Surg; 2022 Jun; 35(6):1208-1216. PubMed ID: 35078386
[No Abstract] [Full Text] [Related]
14. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
17. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
18. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
[TBL] [Abstract][Full Text] [Related]
19. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
